The REMIND Study- SPARK Neuro Software Study

The aim of this study is to collect data to support development of an algorithm to determine whether applying machine-learning techniques to eyes open/eyes closed resting-state electroencephalography (EEG) can characterize patient's cognitive status and detect the presence or absence of AD on the basis of the patient's EEG.

Inclusion criteria

• Age 55 to 85 at the time of consent
• Informant available and willing (remotely or in-person) to provide information about sleep patterns and cognitive functioning who spends >8 hours per week with primary subject
• Subject or Legally Authorized Representative (LAR) has the ability to provide informed consent and comply with the protocol.

Exclusion criteria

• Unable to remain still for up to 30 minutes during EEG data recording
• Subjects currently on and unable to wash out concomitant medications, including: 1) opiates; 2) benzodiazepines and nonbenzodiazepine hypnotics; 3) sedative antihistamines; 4) tricyclic anti-depressants; 5) skeletal muscle relaxants; 6) antiepileptics; 7) antipsychotics; 8) antimanic agents; 9) THC; 10) anticholinergics
• Previous history of craniotomy
• Medical or psychiatric illness that would interfere with study participation
• History of epilepsy or chronic seizure disorder
• Presence of non-dental metal in head
• Currently experiencing a skin disease on scalp that would affect electrode contacts
• Subject meets at least one of the following criteria:

• Diagnosis of cognitive impairment from various underlying pathologies as indicated by one of the diagnostic codes listed in Appendix A (protocol)
• MMSE score of 27 or less
• Treating physician or PI have documented that the patient is cognitively impaired, with judgment of cognitive impairment having been made within the 6 months prior to enrollment
• Substance Use Disorder, including Alcohol